Sequential blinded treatment decisions in ALK-positive non-small cell lung cancers in the era of precision medicine

• J. Remon ^[1] ; F. Tabbò ^[2] ; B. Jimenez ^[3] ; A. Collazo ^[3] ; J. de Castro ^[3] ; S. Novello ^[2]
  1. [1] Department of Medical Oncology, Centro Integral Oncológico Clara Campal (HM-CIOCC), Hospital HM Delfos, HM Hospitales, Avinguda de Vallcarca, 151, 08023 Barcelona, Spain
  2. [2] Thoracic Oncology Unit, Department of Oncology, University of Torino, Regione Gonzole, 10, 10043 Orbassano (TO), Turin, Italy
  3. [3] Medical Oncology Department, Centro Integral Oncológico Clara Campal Madrid, HM Sanchinarro, Calle Oña, 10, 28050 Madrid, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 22, Nº. 9, 2020, págs. 1425-1429
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Next-generation ALK TKIs have become the new standard of care in first-line setting in advanced ALK-positive NSCLC patients. However, sequential strategies at progression are relevant, as may have an impact on patients’ outcome. In this commentary we discuss whether genomic-tailored strategies at progression would be more suitable for improving outcome of ALK-positive NSCLC patients.